A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 28.6K citations

Surgical Oncology, Recist Guideline, Medicine +9

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Thierry Conroy, Françoise Desseigne, Marc Ychou et al. · New England Journal of Medicine · 2011 · 7.6K citations · Full text

Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

Malcolm J. Moore, David Goldstein, John Hamm et al. · Journal of Clinical Oncology · 2007 · 3.8K citations

WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI: Ethical Principles for Medical Research Involving Human Subjects

Journal of obstetrics and gynaecology research · 2001 · 3.5K citations · Full text

Medical Ethics, Biomedical Ethic, Global Health +11

Tumor-suppressive pathways in pancreatic carcinoma.

Ester Rozenblum, Mieke Schutte, Michael Goggins et al. · PubMed · 1997 · 699 citations

Oncology, Pancreatic Cancer, Single Tumor +13